Dr. Vaidya’s

Mumbai, India Founded: 2016 • Age: 10 yrs Listed Acquired By RPSG Ventures
Manufacturer of Ayurvedic products
Request Access
Report Incorrect Data
Page last updated

About Dr. Vaidya’s

Dr. Vaidya’s is a publicly listed company based in Mumbai (India) founded in 2016 by Sheetal Biren Vaidya and Arjun Vaidya, and was acquired by RPSG Ventures in June 2019. Manufacturer of Ayurvedic products. The company has 483 employees. Its chief executive, as recorded, is Chirag Gada. Its website drvaidyas.com draws about 292 thousand monthly visits. Its Indian entity Rpsg Ventures Limited reported revenue of ₹11,453 Cr. Its focus areas include HealthTech, Healthcare Booking Platforms, Pharmacies and Alternative Medical Products. Its competitors include Patanjali Ayurved, LifeChart Ayurveda and Upakarma; 3 of its 3 listed competitors have raised funding.

Company details

Dr. Vaidyas was founded in 2016 in Mumbai, India, as a manufacturer of Ayurvedic products. Offerings include remedies for allergy and cold, hair care, oral care, diabetes, skin care, and additional categories. Products are distributed through the companys clinic, offline retail stores, and online channels, focusing on traditional Ayurvedic formulations in the health and wellness sector.

  • Headquarters Mumbai, India
  • Employees 483
  • Founders Sheetal Biren Vaidya, Arjun Vaidya
  • Stage Acquired
  • Sectors
    Healthcare
  • Website category Health
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website drvaidyas.com
  • Social LinkedIn Facebook YouTube
  • Acquired by RPSG Ventures (Jun 2019)
  • Legal Name Rpsg Ventures Limited
  • Date of Incorporation 07 Feb, 2017
  • Jurisdiction Kolkata, West Bengal, India
Operational Areas
Healthcare → Digital Health & Telemedicine
Key Metrics
  • Market Cap
    ₹2,875 Cr

    RPSGVENT · NSE

  • Share Price
    ₹883.20

    +1.63% today

  • Revenue
    ₹11,323 Cr

    FY 2025-26 · +17.9% YoY

  • EBITDA
    ₹1,505 Cr

    Margin 13.3%

  • Net Profit
    −₹138 Cr

    FY 2025-26 · -108.0% YoY

  • ROE
    0.1%

    ROCE 9.6%

  • Debt / Equity
    2.78

    Interest cover 85.7x

  • Investors
    RPSG Ventures
  • Employee Count
    483
  • Acquired by
    RPSG Ventures

    (Jun 2019)

Apps and channels of Dr. Vaidya’s

its YouTube channel Dr. Vaidya's has 23.1K subscribers and 30 videos.

Dr. Vaidya's
YouTube 23.1K subscribers 30 videos Howto & Style
Open channel

Videos from Dr. Vaidya’s

The most watched videos on Dr. Vaidya’s's YouTube channel, Dr. Vaidya's (23.1K subscribers). Click a video to play it here.

For Stamina On the Go, Dr. Vaidya's Lo | Shilajit Gold Resin Softgel Capsules
3.9M views
Shilajit Benefits for Men ft. Karanvir Bohra | Pure Shilajit + 24K Gold Bhasma in Easy Softgel Form
2.4M views
Weight Ko Kaho Wait | Dr. Vaidya’s Apple Cider Vinegar Fizz | Reduce Belly Fat in 3 Months* |
2.1M views
Weight Ko Kaho Wait | Dr. Vaidya’s Apple Cider Vinegar | Reduce Belly Fat in 3 Months* |
1.4M views

More on Dr. Vaidya's.

Investors in Dr. Vaidya’s

Dr. Vaidya’s has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include RPSG Ventures.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
RPSG Ventures
Early growth stage companies are invested in across multiple sectors.
2017rpsgventuresltd.comKolkata, India
Premium access

Investor details for Dr. Vaidyas

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Rpsg Ventures Limited (Dr. Vaidya’s)

Rpsg Ventures Limited is the primary company behind Dr. Vaidya’s. The boards of the 2 registered companies of Dr. Vaidya’s currently have 10 directors; the longest-serving is Kalaikuruchi Jairaj, appointed in 2018. 24 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Kalaikuruchi Jairaj
DIN 01875126
Director14 Nov 20187 yrs 11 moRpsg Ventures Limited
Arjun Kumar
DIN 00139736
Director14 Nov 20187 yrs 11 moRpsg Ventures Limited
Sudip Kumar Ghosh
DIN 09070464
Company Secretary14 Nov 20187 yrs 11 moRpsg Ventures Limited
Sanjiv Goenka
DIN 00074796
Director14 Nov 20187 yrs 11 moRpsg Ventures Limited
Shashwat Goenka
DIN 03486121
Director14 Nov 20187 yrs 11 moRpsg Ventures Limited
Gopal Rathi
DIN 00553066
Director03 Jun 20197 yrs 5 moHerbolab India Private Limited
Srikanth Ramachandra Murthy Gopishetty
DIN 07383622
Director03 Jun 20197 yrs 5 moHerbolab India Private Limited
Kusum Dadoo
DIN 06967827
Director23 Sep 20215 yrs 1 moRpsg Ventures Limited
Vikas Jain
DIN 11082395
Director16 May 20251 yr 5 moHerbolab India Private Limited
Urvashi Bhura
DIN 10515868
Director02 Mar 20268 moHerbolab India Private Limited

People of Dr. Vaidya’s

3 people are tracked at Dr. Vaidya’s (3 in leadership); the tracked headcount is 483.

NameRoleGroup
Sheetal Biren Vaidya
Co-FounderLeadership
Arjun Vaidya
FounderLeadership
Chirag Gada
CEOLeadership
Premium access

Complete people profiles for Dr. Vaidya’s

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Dr. Vaidya’s

Dr. Vaidya’s is a publicly listed company on the NSE with ticker symbol RPSGVENT in India, operating in the IT - Software sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • Listed onNSE: RPSGVENT
  • Listed entityRpsg Ventures Limited
  • Exchange sectorIT - Software

Financials of Dr. Vaidya’s

Exchange-reported figures of Rpsg Ventures Limited, the listed company behind Dr. Vaidya’s (NSE: RPSGVENT).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹11,323 Cr
+17.8% YoY
EBITDA
₹1,505 Cr
+9.6% YoY
Profit After Tax
−₹138 Cr
-108.0% YoY
Net Worth
₹2,506 Cr
-5.9% YoY
Total Assets
₹15,604 Cr
+14.3% YoY
Total Debt
₹8,243 Cr
+34.0% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue11,3239,6087,9517,1666,6705,5994,608
Revenue growth+17.9%+20.9%+11.0%+7.4%+19.1%+21.5%-
EBITDA1,5051,3731,250803887587404
EBITDA margin+13.3%+14.3%+15.7%+11.2%+13.3%+10.5%+8.8%
Profit before tax276374377120508294114
Net profit(138)(66.49)(42.62)(150)130(82.76)(78.85)
Net profit margin-1.2%-0.7%-0.5%-2.1%+2.0%-1.5%-1.7%
EPS (₹)(41.70)(14.82)(12.83)(51.74)49.32(36.10)(25.63)
Balance sheet
Total assets15,60413,64611,88810,99110,8655,2215,615
Net worth2,5062,6632,6672,4052,5262,1592,326
Total debt8,2436,1524,2113,4142,8071,7081,912
Cash & bank917951689488232167374
Net working capital1,1001,32990625557.11396912
Cash flow
Cash from operations1,2331,0981,038726662901184
Cash from investing(2,110)(1,589)(1,137)(719)(1,453)(458)93.98
Cash from financing837754291252855(652)(79.49)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue3,2433,5762,9272,7562,6682,9712,5412,385
Revenue growth (YoY)+21.6%+20.4%+15.2%+15.6%+23.2%+18.1%--
Other income14016.5574.219.0338.0317.5866.8418.04
EBITDA420664367223306600335268
EBITDA margin+12.9%+18.6%+12.5%+8.1%+11.5%+20.2%+13.2%+11.2%
Depreciation13212813012412311010394.69
Interest244242251213211198200190
Profit before tax18431061.08(105)10.3631098.141.09
Tax69.0556.8513331.1651.4958.9085.8246.70
Net profit115253(72.00)(136)(41.13)25112.32(45.61)
EPS (₹)26.7427.53(17.38)(33.71)(15.72)25.11(3.96)(18.13)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue27022616216216211463.90
Revenue growth+20.0%+39.6%0.0%0.0%+41.7%+78.4%-
EBITDA60.0137.3936.361.9169.2955.365.68
EBITDA margin+22.2%+16.6%+22.5%+1.2%+42.9%+48.6%+8.9%
Profit before tax246199178131198170176
Net profit171145129116151127174
Net profit margin+63.1%+64.2%+79.7%+71.9%+93.2%+111.7%+272.7%
EPS (₹)54.4244.8439.0825.8454.3148.0265.74
Balance sheet
Total assets4,0243,1712,8732,4482,3091,8281,699
Net worth3,0082,8582,7142,2882,2091,8161,689
Total debt99829414114583.960.000.00
Cash & bank63.7714510233.6061.5420.79102
Net working capital54336537892.77(77.89)8.78111
Cash flow
Cash from operations(19.37)16638.0874.6918671.44(0.15)
Cash from investing(711)(238)(235)(150)(458)(153)38.14
Cash from financing64211526547.583120.000.00
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue75.1265.1310156.3856.3756.3874.3770.38
Revenue growth (YoY)+33.3%+15.5%+36.3%-19.9%+39.6%+39.6%--
Other income16.7416.7121517.5214.6315.541608.83
Total expenses56.7150.0948.3954.3656.2851.4645.9461.73
EBITDA18.4115.0452.982.020.094.9228.438.65
EBITDA margin+24.5%+23.1%+52.3%+3.6%+0.2%+8.7%+38.2%+12.3%
Depreciation4.184.014.073.933.713.582.900.80
Interest28.2726.4332.5212.048.218.947.477.18
Profit before tax2.701.312323.572.807.941789.50
Tax0.940.2761.930.980.792.1644.372.04

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 07 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue3,2433,5762,9272,7562,6682,9712,5412,385
Revenue growth (YoY)+21.6%+20.4%+15.2%+15.6%+23.2%+18.1%--
Other income14016.5574.219.0338.0317.5866.8418.04
EBITDA420664367223306600335268
EBITDA margin+12.9%+18.6%+12.5%+8.1%+11.5%+20.2%+13.2%+11.2%
Depreciation13212813012412311010394.69
Interest244242251213211198200190
Profit before tax18431061.08(105)10.3631098.141.09
Tax69.0556.8513331.1651.4958.9085.8246.70
Net profit115253(72.00)(136)(41.13)25112.32(45.61)
EPS (₹)26.7427.53(17.38)(33.71)(15.72)25.11(3.96)(18.13)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue11,3239,6087,9517,1666,6705,5994,608
Revenue growth+17.9%+20.9%+11.0%+7.4%+19.1%+21.5%-
Other income13010855.6417412463.7836.91
Total expenses9,8188,2356,7016,3635,7835,0124,205
Employee cost5,8845,2414,1004,0174,0643,5882,896
EBITDA1,5051,3731,250803887587404
EBITDA margin+13.3%+14.3%+15.7%+11.2%+13.3%+10.5%+8.8%
Depreciation487370302305291249225
Interest872737627552211107102
Profit before tax276374377120508294114
Tax27521018017917023637.79
Net profit(138)(66.49)(42.62)(150)130(82.76)(78.85)
Net profit margin-1.2%-0.7%-0.5%-2.1%+2.0%-1.5%-1.7%
EPS (₹)(41.70)(14.82)(12.83)(51.74)49.32(36.10)(25.63)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital33.0933.0933.0929.5129.5126.5126.51
Reserves & surplus2,4732,6302,6342,3762,4972,1322,300
Shareholders' funds (net worth)2,5062,6632,6672,4052,5262,1592,326
Minority interest1,8761,9251,7931,6011,5491,3011,327
Secured loans5,4733,6892,6141,8811,506511392
Unsecured loans2,7702,4631,5971,5321,3011,1971,520
Total debt8,2436,1524,2113,4142,8071,7081,912
Total liabilities15,60413,64611,88810,99110,8655,2215,615
Assets
Gross block14,37112,59411,25010,88410,7895,2794,972
Net block12,71411,27210,0669,9569,9344,0783,983
Capital work in progress64.5158.7722.536.999.345.147.43
Investments75355443843949524093.84
Inventories97.9479.2076.6168.9464.3952.2852.56
Sundry debtors2,2791,8081,3401,1091,023608603
Cash & bank balances917951689488232167374
Loans & advances920766612510472529452
Total current assets4,2143,6042,7182,1761,7911,3561,482
Total current liabilities3,1142,2751,8121,9211,734960570
Net working capital1,1001,32990625557.11396912
Total assets15,60413,64611,88810,99110,8655,2215,615
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash938675484225161370172
Net cash from operating activities1,2331,0981,038726662901184
Net cash from investing activities(2,110)(1,589)(1,137)(719)(1,453)(458)93.98
Net cash from financing activities837754291252855(652)(79.49)
Net change in cash(39.63)26319225963.83(209)199
Closing cash917951689488232167374
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+17.9%+20.9%+11.0%+7.4%+19.1%+21.5%-
EBITDA growth+9.6%+9.9%+55.6%-9.5%+51.1%+45.4%-
PBT growth-26.2%-0.7%+213.4%-76.4%+72.7%+159.3%-55.3%
Net income growth-108.0%-56.0%+71.6%-215.4%+257.2%-5.0%-
Revenue CAGR (3Y)+16.5%+12.9%+12.4%+15.9%+15.1%+41.1%-
EBITDA CAGR (3Y)+23.3%+15.7%+28.6%+25.8%+31.8%+39.4%-
Profitability & leverage
Net income margin+0.0%+1.7%+2.5%-0.8%+5.1%+1.0%+1.6%
Return on capital employed+9.6%+10.2%+10.3%+7.2%+10.9%+11.4%+5.0%
Return on net worth+0.1%+6.1%+7.7%-2.4%+14.5%+3.2%+2.8%
Debt / equity2.781.941.501.260.960.810.60
Long-term debt / equity1.000.730.630.630.550.410.26
Interest cover85.6673.4866.12110.8435.4731.7857.17
Efficiency & per share
Fixed asset turnover0.840.810.710.660.831.091.04
Inventory turnover127.84123.33109.25107.50114.34106.8286.18
Debtors turnover5.546.116.496.728.189.258.86
EPS (₹)(41.70)(14.82)(12.83)(51.74)49.32(36.10)(25.63)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)757.26804.81805.99815.12947.30814.41877.56
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue75.1265.1310156.3856.3756.3874.3770.38
Revenue growth (YoY)+33.3%+15.5%+36.3%-19.9%+39.6%+39.6%--
Other income16.7416.7121517.5214.6315.541608.83
Total expenses56.7150.0948.3954.3656.2851.4645.9461.73
EBITDA18.4115.0452.982.020.094.9228.438.65
EBITDA margin+24.5%+23.1%+52.3%+3.6%+0.2%+8.7%+38.2%+12.3%
Depreciation4.184.014.073.933.713.582.900.80
Interest28.2726.4332.5212.048.218.947.477.18
Profit before tax2.701.312323.572.807.941789.50
Tax0.940.2761.930.980.792.1644.372.04
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue27022616216216211463.90
Revenue growth+20.0%+39.6%0.0%0.0%+41.7%+78.4%-
Other income263190160146135115170
Total expenses21018812516092.2158.6458.22
Employee cost10289.8948.4035.8927.6727.7626.04
EBITDA60.0137.3936.361.9169.2955.365.68
EBITDA margin+22.2%+16.6%+22.5%+1.2%+42.9%+48.6%+8.9%
Depreciation15.295.202.702.181.120.540.07
Interest61.7123.1515.1213.845.600.000.00
Profit before tax246199178131198170176
Tax65.8651.0448.7855.2253.1442.811.49
Net profit171145129116151127174
Net profit margin+63.1%+64.2%+79.7%+71.9%+93.2%+111.7%+272.7%
EPS (₹)54.4244.8439.0825.8454.3148.0265.74
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital33.0933.0933.0929.5129.5126.5126.51
Reserves & surplus2,9752,8252,6812,2582,1801,7901,663
Shareholders' funds (net worth)3,0082,8582,7142,2882,2091,8161,689
Secured loans72728014184.5483.960.000.00
Unsecured loans27114.170.0060.000.000.000.00
Total debt99829414114583.960.000.00
Total liabilities4,0243,1712,8732,4482,3091,8281,699
Assets
Gross block14513360.9559.6549.5814.871.95
Net block11812254.4055.7447.8514.261.88
Capital work in progress0.370.350.350.350.350.350.00
Investments3,0622,6852,4162,2922,2291,7791,553
Inventories0.000.000.000.000.000.000.00
Sundry debtors56.811.130.810.490.163.2820.35
Cash & bank balances63.7714510233.6061.5420.79102
Loans & advances7305364592328.022.391.45
Total current assets85068256126669.7226.46124
Total current liabilities30731718317414817.6813.15
Net working capital54336537892.77(77.89)8.78111
Total assets4,0243,1712,8732,4482,3091,8281,699
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash14510233.5761.5120.7610264.42
Net cash from operating activities(19.37)16638.0874.6918671.44(0.15)
Net cash from investing activities(711)(238)(235)(150)(458)(153)38.14
Net cash from financing activities64211526547.583120.000.00
Net change in cash(88.93)43.1968.28(27.94)40.75(81.65)37.99
Closing cash63.7714510233.6061.5420.79102
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+20.0%+39.6%0.0%0.0%+41.7%+78.4%-
EBITDA growth+60.5%+2.8%+1803.7%-97.2%+25.2%+874.7%-
PBT growth+23.3%+12.0%+35.5%-33.5%+16.3%-3.2%+137.0%
Net income growth+18.0%+12.4%+10.9%-22.9%+18.3%-27.0%-
Revenue CAGR (3Y)+18.8%+11.8%+12.3%+36.2%+37.2%+65.6%-
EBITDA CAGR (3Y)+215.6%-18.6%-13.1%-30.5%+78.1%+194.8%-
Profitability & leverage
Net income margin+66.6%+65.8%+80.1%+47.2%+89.6%+111.7%+272.7%
Return on capital employed+8.6%+7.4%+7.3%+9.0%+9.8%+9.7%+10.9%
Return on net worth+6.1%+5.3%+5.2%+5.2%+7.2%+7.3%+10.9%
Debt / equity0.220.080.060.050.020.000.00
Long-term debt / equity0.170.060.030.040.020.000.00
Interest cover137.9971.9244.92-5,125.938.210.000.00
Efficiency & per share
Fixed asset turnover1.952.322.682.965.0113.5665.54
Inventory turnover0.000.000.000.000.000.000.00
Debtors turnover9.34232.47248.46496.9293.909.652.83
EPS (₹)54.4244.8439.0825.8454.3148.0265.74
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)909.11863.67820.14775.22828.19685.17637.18

Timeline of Dr. Vaidya’s

2 dated milestones of Dr. Vaidya’s across 3 years, from founding to its latest funding, stage changes and deals.

  1. Founded Dr. Vaidya’s is founded.
  2. Exit Acquired by RPSG Ventures.

Competitors of Dr. Vaidya’s

Dr. Vaidya’s has 3 listed competitors in our database, 3 of them funded. They include Patanjali Ayurved, LifeChart Ayurveda and Upakarma.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Patanjali Ayurved
patanjaliayurved.net2006Haridwar, India$430,6241,460
Ayurvedic medicines and nutraceuticals are offered via an online platform.
LifeChart Ayurveda
lifechartayurveda.in2022Gurugram, India$1.06M
Gut health-tech company developing ayurvedic healthcare solutions
Upakarma
upakarma.com2017Delhi, India$55,8223
Internet first D2C brand offering ayurvedic health, beauty, immunity & wellness products
Premium access

Detailed competitors of Dr. Vaidyas

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Dr. Vaidya’s

The website of Dr. Vaidya’s (drvaidyas.com) receives about 292.3K visits a month and ranks #213,781 among all websites worldwide, #6,998 in Health.

  • Monthly visits
    292.3K

    ▲ 16.1% vs previous month

  • Unique visitors
    162.8K

    per month

  • Global rank
    #213,781

    among all websites

  • Category rank
    #6,998

    Health · Health

Similar websites

Websites whose visitors overlap most with Dr. Vaidya’s. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Ayurvedagram
ayurvedagram.com
100%
24.5K#1,102,666View details
Vedi Herbals
vediherbals.com
96%
44.3K#673,440View details
Kapiva
kapiva.in
90%
3.5M#16,572View details
Bold Care
boldcare.in
89%
194.3K#234,509View details
MyUpchar
myupchar.com
88%
3.5M#17,980View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 40 similar websites and full traffic analytics for Dr. Vaidya’s

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 40 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Digital Health & Telemedicine

3 companies that operate in the same segment as Dr. Vaidya’s (Digital Health & Telemedicine) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Tata 1mg
Provider of an online pharmacy with doctor listing and teleconsultation services
2015Delhi, Delhi, IndiaUSD 199.65 MUSD 328.97 M5,212
MediBuddy
Online platform offering multiple healthcare services
2013Bengaluru, Karnataka, IndiaUSD 199.22 MUSD 62.4 M52
SastaSundar
An online marketplace for healthcare products is operated.
2011Kolkata, West Bengal, IndiaUSD 38.26 M
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Dr. Vaidya’S

RPSGVENT: Q2 CONS NET PROFIT 884.9M RUPEES VS LOSS 520.2M (YOY)
Exchange Update • 2 days ago
RPSGVENT: Q2 REVENUE 32.43B RUPEES VS 26.68B (YOY)
Exchange Update • 2 days ago
RPSGVENT: Q2 EBITDA 4.2B RUPEES VS 3.06B (YOY); Q2 EBITDA MARGIN 12.93% VS 11.46% (YOY)
Exchange Update • 2 days ago
RPSG Ventures June-Quarter Consol Net Profit 910.9 Million Rupees
Reuters • 2 months ago
Will Aiden Markram lead LSG in IPL 2026 after Rishabh Pant's exit? South African puts the ball in Sanjiv Goenka's court
Mint • 3 months ago
RPSG Ventures March-Quarter Consol Net Loss 575 Million Rupees
Reuters • 5 months ago
How are Ventureast, RPSG Ventures faring as FMCG giant snaps up portfolio firm?
VCCircle • 6 months ago
RPSG Ventures Says RPSG Brands MENA Incorporated To Explore FMCG Trading Opportunities In India, Abroad
Reuters • 6 months ago
RPSG Ventures Says Sudhir Langer Steps Down As Whole-Time Director Effective March 31, 2026
Reuters • 7 months ago
Indian shares extend gains as US pushes Iran ceasefire plan
Reuters • 7 months ago
Premium access

Complete news archive for Dr. Vaidyas

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Dr. Vaidya’s

Dr. Vaidya’s was founded in 2016.

Dr. Vaidya’s is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Chirag Gada is the CEO of Dr. Vaidya’s, as recorded in our data.

Dr. Vaidya’s has 483 employees.

The primary company behind Dr. Vaidya’s, Rpsg Ventures Limited, reported revenue of ₹11,453 Cr for FY 2026, up 18% year on year.

Dr. Vaidyas was founded in 2016 in Mumbai, India, as a manufacturer of Ayurvedic products. Offerings include remedies for allergy and cold, hair care, oral care, diabetes, skin care, and additional categories. Products are distributed through the companys clinic, offline retail stores, and online channels, focusing on traditional Ayurvedic formulations in the health and wellness sector.

Dr. Vaidya’s's top competitors include Patanjali Ayurved, LifeChart Ayurveda and Upakarma.

Yes, Dr. Vaidya’s is publicly traded on NSE under the ticker symbol RPSGVENT.

Dr. Vaidya’s has 1 investor. Key investors include RPSG Ventures.

Dr. Vaidya’s is associated with 2 legal entities: Rpsg Ventures Limited, Herbolab India Private Limited.

Yes. Dr. Vaidya’s was acquired by RPSG Ventures in June 2019.

The legal entities of Dr. Vaidya’s currently have 12 directors, including Gopal Rathi, Srikanth Ramachandra Murthy Gopishetty, Urvashi Bhura and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available